

## Pharmaceutical compositions for treating hyperhomocysteinaemia caused by drugs

Patent Number WO 2001056609 A1 9 August, 2001

PCT Int. Appl., 19 pp.

### Abstract

The invention relates to a pharmaceutical composition for producing H<sub>2</sub>-receptor blockers (cimetidine), non-steroidal analgesics (ibuprofen, indometacin), antidepressants (lithium), anti-epileptic agents (phenytoin, carbamazepin), immunosuppressants (cyclosporin, methotrexate), methylxanthine (theophyllin), biguanides (metformin) and lipid reducers (fibrates, anion exchangers, nicotinic acid and nicotinic acid analogs) or drugs for treating hypertension, containing a combination of a pharmaceutical active agent which causes hyperhomocysteinemia and at least one of the following active agents: cobalamine (cyano-, hydroxo-, methyl-), folic acid (pteroylglutamic acid, methyltetrahydrofolate, folinic acid), vitamin B<sub>6</sub> (pyridoxine chloride), betaine or N-acetylcysteine. According to a novel observation, hyperhomocysteinemia (a high level of the amino acid homocysteine in the blood plasma) is caused by the intake of drugs for lowering blood pressure (diuretics, calcium antagonists, ACE inhibitors or angiotensin-II receptor antagonists), non-steroidal analgesics, antidepressants (lithium), immunosuppressants, methylxanthine (theophyllin), biguanides (metformin) or lipid reducers (fibrates, anion exchangers, nicotinic acid and nicotinic acid analogs). Thus a dragee contained: hydrochlorothiazide 25 mg; cyanocobalamine 1000 µg; pteroylglutamic acid 100 µg; pyridoxine chloride 2 mg; and excipients.

### Inventor(s)

Westphal, Sabine; Dierkes, Jutta; Luley, Klaus

### Assignee(s)

Germany

### Application Information

WO 2000-EP8801 8 September, 2000

### Priority Information

DE 2000-10004651 A 3 February, 2000

### Patent Information

Number	Kind	Date	Application	Date
(1) WO 2001056609	A1	9 August, 2001	WO 2000-EP8801	8 September, 2000
DE 10004651	A1	16 August, 2001	DE 2000-10004651	3 February, 2000

(1) - W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

Number	Kind	Date	Application	Date
(1) WO 2000056404	B1	21 December, 2000		

(1) - W: AU, CA, NZ, US; RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

☐ 01 August 2003 at 15:01 - ANSWER 14 OF 52

HCAPLUS ©2003 ACS on STN  
2000:688052-Full Text

## Oral combinations of hydroxocobalamin and folic acid

Patent Number WO 2000056295 A2 28 September, 2000

PCT Int. Appl., 15 pp.

### Abstract

A variety of conditions is known wherein vitamin B12 is deficient, or wherein the administration of vitamin B12 is beneficial. Classically, once detected and if appropriate, these have been treated by the parenteral administration of vitamin B12 as oral administration is believed to be ineffective. Available oral preps. of vitamin B12 all contain cyanocobalamin which is less desirable than hydroxocobalamin. In accordance with the invention, effective oral formulations are provided which include, in addition to the hydroxocobalamin, folic acid or other folate precursor. The formulation for oral administration should be such as to provide, for a given daily dose, 0.5 to 50 mg hydroxocobalamin and 0.5 to 50 mg folic acid.

### Inventor(s)

Horrobin, David Frederick; Gouaille, Christina

### Assignee(s)

Kilgowan Limited, UK

### Application Information

WO 2000-GB1093 23 March, 2000

### Priority Information

GB 1999-6740 A 23 March, 1999  
WO 2000-GB1093 W 23 March, 2000

### Patent Information

Number	Kind	Date	Application	Date
WO 2000056295	A2	28 September, 2000	WO 2000-GB1093	23 March, 2000
(1) WO 2000056295	A3	28 March, 2002		
US 2002010148	A1	24 January, 2002	US 2000-534417	23 March, 2000
US 6369041	B2	9 April, 2002		
(2) EP 1210089	A2	5 June, 2002	EP 2000-912767	23 March, 2000

(1) - W: AU, CA, NZ; RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE  
(2) - R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY

☐ 01 August 2003 at 15:01 - ANSWER 15 OF 52

HCAPLUS ©2003 ACS on STN  
2000:665507-Full Text